Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 1/2011

Open Access 01-03-2011

HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies

Authors: Eva A. Operskalski, Andrea Kovacs

Published in: Current HIV/AIDS Reports | Issue 1/2011

Login to get access

Abstract

World-wide, hepatitis C virus (HCV) accounts for approximately 130 million chronic infections, with an overall 3% prevalence. Four to 5 million persons are co-infected with HIV. It is well established that HIV has a negative impact on the natural history of HCV, including a higher rate of viral persistence, increased viral load, and more rapid progression to fibrosis, end-stage liver disease, and death. Whether HCV has a negative impact on HIV disease progression continues to be debated. However, following the introduction of effective combination antiretroviral therapy, the survival of coinfected individuals has significantly improved and HCV-associated diseases have emerged as the most important co-morbidities. In this review, we summarize the newest studies regarding the pathogenesis of HIV/HCV coinfection, including effects of coinfection on HIV disease progression, HCV-associated liver disease, the immune system, kidney and cardiovascular disease, and neurologic status; and effectiveness of current anti-HIV and HCV therapies and proposed new treatment strategies.
Literature
1.
Alter MJ: Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44(1 Suppl):S6–9.CrossRefPubMed
2.
3.
Frederick T, Burian P, Terrault N, et al.: Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS 2009, 23(11):915–23.CrossRefPubMed
4.
Tohme RA and Holmberg SD: Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010, 52(4):1497–505.CrossRefPubMed
5.
van de Laar TJ, Paxton WA, Zorgdrager F, et al.: Sexual Transmission of Hepatitis C Virus in Human Immunodeficiency Virus-Negative Men Who Have Sex With Men: A Series of Case Reports. Sex Transm Dis 2010.
6.
7.
Soriano V, Mocroft A, Rockstroh J, et al.: Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008, 198(9):1337–44.CrossRefPubMed
8.
Laskus T, Operskalski EA, Radkowski M, et al.: Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women. J Infect Dis 2007, 195(1):124–33.CrossRefPubMed
9.
Moreno S, Garcia-Samaniego J, Moreno A, et al.: Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat 2009, 16(4):249–58.CrossRefPubMed
10.
Castera L: Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009, 16(5):300–14.CrossRefPubMed
11.
Sulkowski MS: Management of hepatic complications in HIV-infected persons. J Infect Dis 2008, 197 Suppl 3:S279–93.CrossRefPubMed
12.
Neukam K, Macias J, Mira JA, and Pineda JA: A review of current anti-HCV treatment regimens and possible future strategies. Expert Opin Pharmacother 2009, 10(3):417–33.CrossRefPubMed
13.
14.
Webster DP, Klenerman P, Collier J, and Jeffery KJ: Development of novel treatments for hepatitis C. Lancet Infect Dis 2009, 9(2):108–17.CrossRefPubMed
15.
• Franciscus A, (Editor): Hepatitis C treatments in current clinical development. HCV Advocate 2010. This is an annotated tabulated summary of HCV drugs in clinical development.
16.
Rotman Y and Liang TJ: Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 2009, 83(15):7366–74.CrossRefPubMed
17.
Roe B and Hall WW: Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. Expert Rev Mol Med 2008, 10:e30.CrossRefPubMed
18.
Kim AY and Chung RT: Coinfection with HIV-1 and HCV—a one-two punch. Gastroenterology 2009, 137(3):795–814.CrossRefPubMed
19.
Blackard JT and Sherman KE: HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008, 15(5):323–30.CrossRefPubMed
20.
Martin-Thormeyer EM and Paul RH: Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev 2009, 19(2):215–31.CrossRefPubMed
21.
Soriano V, Vispo E, Labarga P, et al.: Viral hepatitis and HIV co-infection. Antiviral Res 2010, 85(1):303–15.CrossRefPubMed
22.
Chen TY, Ding EL, Seage Iii GR, and Kim AY: Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009, 49(10):1605–15.CrossRefPubMed
23.
d’Arminio Monforte A, Cozzi-Lepri A, Castagna A, et al.: Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis 2009, 49(4):612–22.CrossRefPubMed
24.
•• Kovacs A, Karim R, Mack WJ, et al.: Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 2010, 201(6):823–34. This study showed that HCV-viremic women with HIV co-infection who have high levels of T-cell activation may have increased AIDS risk, and suggested that earlier treatment of HIV and HCV infections may be beneficial.
25.
Kovacs A, Al-Harthi L, Christensen S, et al.: CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis 2008, 197(10):1402–7.CrossRefPubMed
26.
Gonzalez VD, Falconer K, Blom KG, et al.: High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009, 83(21):11407–11.CrossRefPubMed
27.
Korner C, Kramer B, Schulte D, et al.: Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients. Clin Sci (Lond) 2009, 116(12):861–70.CrossRef
28.
Potter M, Odueyungbo A, Yang H, et al.: Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 2010, 24(12):1857–65.CrossRefPubMed
29.
Peters L, Mocroft A, Soriano V, et al.: Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr 2009, 50(5):457–63.CrossRefPubMed
30.
Yacisin K, Maida I, Rios MJ, et al.: Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. AIDS Res Hum Retroviruses 2008, 24(7):935–40.CrossRefPubMed
31.
Al-Harthi L, Voris J, Du W, et al.: Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells. J Infect Dis 2006, 193(9):1202–10.CrossRefPubMed
32.
•• Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and Adolescents. Department of Health and Human Services. 2009. p. 1–161. These are recent US guidelines for antiretroviral therapy in HIV/HCV co-infection.
33.
Thein HH, Yi Q, Dore GJ, and Krahn MD: Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008, 22(15):1979–91.CrossRefPubMed
34.
Martin-Carbonero L, de Ledinghen V, Moreno A, et al.: Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. J Viral Hepat 2009, 16(11):790–5.CrossRefPubMed
35.
Maida I, Soriano V, Barreiro P, et al.: Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases. AIDS Res Hum Retroviruses 2007, 23(6):801–4.CrossRefPubMed
36.
Smit C, van den Berg C, Geskus R, et al.: Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008, 47(2):221–5.CrossRefPubMed
37.
Sterling RK, Contos MJ, Smith PG, et al.: Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection. Hepatology 2008, 47(4):1118–27.CrossRefPubMed
38.
Machado MV, Oliveira AG, and Cortez-Pinto H: Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology 2010, 52(1):71–8.PubMed
39.
Kuntzen T, Tural C, Li B, et al.: Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS 2008, 22(2):203–10.CrossRefPubMed
40.
Nakamoto N, Kaplan DE, Coleclough J, et al.: Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 2008, 134(7):1927–37, 1937 e1–2CrossRefPubMed
41.
Vali B, Yue FY, Jones RB, et al.: HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection. PLoS One 2008, 3(10):e3454.CrossRefPubMed
42.
Balagopal A, Philp FH, Astemborski J, et al.: Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008, 135(1):226–33.CrossRefPubMed
43.
Tuyama AC, Hong F, Saiman Y, et al.: Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology 2010, 52(2):612–22.CrossRefPubMed
44.
Jang JY, Shao R-X, Lin W, et al.: HIV increases HCV-induced hepatocyte apoptosis. Journal of Hepatology In Press, Accepted Manuscript.
45.
Halfon P, Penaranda G, Carrat F, et al.: Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Aliment Pharmacol Ther 2009, 30(1):61–70.CrossRefPubMed
46.
Merchante N, Rivero A, de Los Santos-Gil I, et al.: Insulin resistance is associated with liver stiffness in HIV/HCV co-infected patients. Gut 2009, 58(12):1654–60CrossRefPubMed
47.
Kirk GD, Astemborski J, Mehta SH, et al.: Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009, 48(7):963–72.CrossRefPubMed
48.
Vergara S, Macias J, Rivero A, et al.: The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007, 45(8):969–74.CrossRefPubMed
49.
Nunes D, Fleming C, Offner G, et al.: Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010, 105(6):1346–53.CrossRefPubMed
50.
Al-Mohri H, Murphy T, Lu Y, et al.: Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007, 44(4):463–9.CrossRefPubMed
51.
Suzman DL, McLaughlin M, Hu Z, et al.: Identification of novel markers for liver fibrosis in HIV/hepatitis C virus coinfected individuals using genomics-based approach. AIDS 2008, 22(12):1433–9.CrossRefPubMed
52.
Ghotb A, Noworolski SM, Madden E, et al.: Adipose tissue and metabolic factors associated with steatosis in HIV/HCV coinfection: histology versus magnetic resonance spectroscopy. J Acquir Immune Defic Syndr 2010.
53.
Lapinski TW, Parfieniuk A, Rogalska-Plonska M, et al.: Prevalence of cryoglobulinaemia in hepatitis C virus- and hepatitis C virus/human immunodeficiency virus-infected individuals: implications for renal function. Liver Int 2009, 29(8):1158–61.CrossRefPubMed
54.
Reingold J, Wanke C, Kotler D, et al.: Association of HIV infection and HIV/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008, 48(2):142–8.CrossRefPubMed
55.
Marks KM, Clarke RM, Bussel JB, et al.: Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2009, 52(5):595–9.CrossRefPubMed
56.
Wyatt CM, Malvestutto C, Coca SG, et al.: The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 2008, 22(14):1799–807.CrossRefPubMed
57.
Fischer MJ, Wyatt CM, Gordon K, et al.: Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr 2010, 53(2):222–6.CrossRefPubMed
58.
Izzedine H, Sene D, Cacoub P, et al.: Kidney diseases in HIV/HCV-co-infected patients. AIDS 2009, 23(10):1219–26.CrossRefPubMed
59.
Bedimo R, Westfall AO, Mugavero M, et al.: Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010, 11(7):462–8.PubMed
60.
Castro IF, Micheloud D, Berenguer J, et al.: Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. AIDS 2010.
61.
Letendre S, Paulino AD, Rockenstein E, et al.: Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007, 196(3):361–70.CrossRefPubMed
62.
Vivithanaporn P, Maingat F, Lin LT, et al.: Hepatitis C virus core protein induces neuroimmune activation and potentiates human immunodeficiency virus-1 neurotoxicity. PLoS One 2010, 5(9).
63.
Aronow HA, Weston AJ, Pezeshki BB, and Lazarus TS: Effects of coinfection with HIV and hepatitis C virus on the nervous system. AIDS Read 2008, 18(1):43–8.PubMed
64.
Hinkin CH, Castellon SA, Levine AJ, et al.: Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis 2008, 27(2):11–7.CrossRefPubMed
65.
Ancuta P, Kamat A, Kunstman KJ, et al.: Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008, 3(6):e2516.CrossRefPubMed
66.
Clifford DB, Smurzynski M, Park LS, et al.: Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology 2009, 73(4):309–14.CrossRefPubMed
67.
Cherry CL, Affandi JS, Brew BJ, et al.: Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV. Neurology 2010, 74(19):1538–42.CrossRefPubMed
68.
Butt AA, McGinnis K, Rodriguez-Barradas MC, et al.: HIV infection and the risk of diabetes mellitus. AIDS 2009, 23(10):1227–34.CrossRefPubMed
69.
Howard AA, Hoover DR, Anastos K, et al.: The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women’s Interagency HIV Study. J Acquir Immune Defic Syndr 2010, 54(2):152–9.PubMed
70.
Collin F, Duval X, Le Moing V, et al.: Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009, 23(8):1021–4.CrossRefPubMed
71.
Pascual-Pareja JF, Caminoa A, Larrauri C, et al.: HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy. AIDS 2009, 23(8):971–5.CrossRefPubMed
72.
Moodie EE, Pant Pai N, and Klein MB: Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS One 2009, 4(2):e4517.CrossRefPubMed
73.
•• Thompson MA, Aberg JA, Cahn P, et al.: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304(3):321–33. These are recent US guidelines for antiretroviral therapy in HIV/HCV co-infection.
74.
Tedaldi E, Peters L, Neuhaus J, et al.: Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008, 47(11):1468–75.CrossRefPubMed
75.
Labarga P, Vispo E, Barreiro P, et al.: Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse. J Acquir Immune Defic Syndr 2010, 53(3):364–8.CrossRefPubMed
76.
Labarga P, Soriano V, Vispo ME, et al.: Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007, 196(5):670–6.CrossRefPubMed
77.
Soriano V, Puoti M, Sulkowski M, et al.: Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007, 21(9):1073–89.CrossRefPubMed
78.
England K, Thorne C, Pembrey L, and Newell ML: Policies and practices for the clinical management of HIV/HCV coinfected children in Europe: an epidemiological survey. Eur J Pediatr 2009, 168(8):915–7.CrossRefPubMed
79.
Iorio A, Marchesini E, Awad T, and Gluud LL: Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. Cochrane Database Syst Rev 2010, (1):CD004888.
80.
Van den Eynde E, Crespo M, Esteban JI, et al.: Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis 2009, 48(8):1152–9.CrossRefPubMed
81.
Sherman KE, Rouster SD, Stanford S, et al.: Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens. J Infect Dis 2010, 201(5):712–9.PubMed
82.
Martin-Carbonero L, Nunez M, Marino A, et al.: Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008, 22(1):15–21.CrossRefPubMed
83.
Opravil M, Sasadeusz J, Cooper DA, et al.: Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008, 47(1):36–49.CrossRefPubMed
84.
Mira JA, Gutierrez-Valencia A, Gil Ide L, et al.: Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clin Infect Dis 2009, 49(8):e84–91.
85.
de Felipe B, Leal M, Soriano-Sarabia N, et al.: HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN/RBV treatment is associated with virologic relapse. J Viral Hepat 2009, 16(1):21–7.CrossRefPubMed
86.
Osinusi A, Rasimas JJ, Bishop R, et al.: HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do. J Acquir Immune Defic Syndr 2010, 53(3):357–63.CrossRefPubMed
87.
Bhattacharya D, Umbleja T, Carrat F, et al.: Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr 2010.
88.
Toma S, Yamashiro T, Arakaki S, et al.: Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha. J Viral Hepat 2009, 16(7):506–12.CrossRefPubMed
89.
Vispo E, Barreiro P, Pineda JA, et al.: Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008, 13(3):429–37.PubMed
90.
Amorosa VK, Slim J, Mounzer K, et al.: The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther 2010, 15(1):91–9.CrossRefPubMed
91.
Reiberger T, Kosi L, Maresch J, et al.: Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. J Infect Dis 2010, 202(1):156-60.CrossRefPubMed
92.
Bani-Sadr F, Lapidus N, Bedossa P, et al.: Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008, 46(5):768–74.CrossRefPubMed
93.
Price P, Murdoch DM, Agarwal U, et al.: Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev 2009, 22(4):651-63.CrossRefPubMed
94.
Ofotokun I, Smithson SE, Lu C, et al.: Liver enzymes elevation and immune reconstitution among treatment-naive HIV-infected patients instituting antiretroviral therapy. Am J Med Sci 2007, 334(5):334–41.CrossRefPubMed
95.
Cicconi P, Cozzi-Lepri A, Phillips A, et al.: Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS 2007, 21(5):599–606.CrossRefPubMed
96.
Pockros PJ, Nelson D, Godofsky E, et al.: R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008, 48(2):385–97.CrossRefPubMed
97.
Roberts SK, Cooksley G, Dore GJ, et al.: Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008, 48(2):398–406.CrossRefPubMed
98.
Shi ST, Herlihy KJ, Graham JP, et al.: Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2009, 53(6):2544–52.CrossRefPubMed
99.
Venkatraman S, Velazquez F, Wu W, et al.: Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease. J Med Chem 2009, 52(2):336–46.CrossRefPubMed
100.
Li H, Tatlock J, Linton A, et al.: Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1 ,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-on e (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J Med Chem 2009, 52(5):1255–8.CrossRefPubMed
101.
Rodriguez-Torres M: On the cusp of change: new therapeutic modalities for HCV. Ann Hepatol 2010, 9 Suppl:123–31.PubMed
102.
Fowell AJ and Nash KL: Telaprevir: a new hope in the treatment of chronic hepatitis C? Adv Ther 2010, 27(8):512–22.CrossRefPubMed
103.
Poordad F, Lawitz E, Shiffman ML, et al.: Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology 2010, 52(4):1208–15.CrossRefPubMed
104.
Thomson EC, Nastouli E, Main J, et al.: Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009, 23(1):89–93.CrossRefPubMed
105.
Matthews GV, Hellard M, Haber P, et al.: Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009, 48(5):650–8.CrossRefPubMed
106.
Schulze Zur Wiesch J, Pieper D, Stahmer I, et al.: Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Clin Infect Dis 2009, 49(3):466–72.CrossRefPubMed
Metadata
Title
HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies
Authors
Eva A. Operskalski
Andrea Kovacs
Publication date
01-03-2011
Publisher
Current Science Inc.
Published in
Current HIV/AIDS Reports / Issue 1/2011
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-010-0071-3

Other articles of this Issue 1/2011

Current HIV/AIDS Reports 1/2011 Go to the issue

ReviewPaper

The Search for Host Genetic Factors of HIV/AIDS Pathogenesis in the Post-Genome Era: Progress to Date and New Avenues for Discovery

ReviewPaper

Point-of-Care Testing

Clinical Trial Report

The Monoclonal CCR5 Antibody PRO-140: The Promise of Once-Weekly HIV Therapy

ReviewPaper

Alterations of the B-Cell Response by HIV-1 Replication

ReviewPaper

Coreceptors and HIV-1 Pathogenesis

ReviewPaper

Combination HIV Prevention: Significance, Challenges, and Opportunities
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits